Background
Lipid metabolism has a potential role in the development and progress of Alzheimer’s disease (AD). Abnormal lipid in the brain has been considered as a histological feature of AD [
1]. The Apolipoprotein E (ApoE) gene is known to play a role in neuronal lipid homeostasis in the brain, and ApoE genotype has been associated with an increased risk of AD [
2]. Genome-wide association studies have shown that lipid metabolism and transport are one of the main pathways involved in the pathological process of AD [
3,
4].
Furthermore, autopsy studies have shown that an abnormal lipid profile in peripheral blood precedes the pathological characteristics of AD [
5‐
7]. A recent meta-analysis of cohort studies found that increased cholesterol in mid-life, not in late-life, is associated with incident dementia in old age [
8]. This current evidence supports an involvement of dyslipidemia in development of AD.
Recent prospective studies with moderate to large sample sizes have suggested that high- density lipoprotein cholesterol (HDL-C), one of the blood lipid parameters, may be inversely associated with the risk of AD [
9‐
11]. However, the relatively small epidemiological studies that have subsequently investigated the association between serum HDL-C and AD risk have yielded inconsistent results [
12,
13]. Inconsistent findings for a link between HDL-C and AD risk may come from misclassification of dementia resulting from varying diagnostic criteria [
11] and insufficient follow-up times to show the effect of HDL-C on incident AD [
8]. In addition, HDL-C measurement is relatively less standardized and less precision, compared with total cholesterol (TC) [
14]. Because clinically meaningful differences in concentrations are small, the HDL-C measurement error might contribute to these conflicting results [
15].
The endothelial lipase (EL, also alternatively named LIPG) plays an important role in HDL metabolism. EL hydrolyzes HDL phospholipids and clears HDL-C from the circulation [
16,
17]. Gain and loss of function studies in mice have indicated that EL is major determinant of HDL-C [
18‐
20]. Genetic variation studies have supported a positive correlation between EL and blood HDL-C in humans [
21,
22]. EL does not affect other lipid-related blood parameters [
23]. EL is secreted by vascular endothelial cells, medial smooth muscle, and macrophages on atherosclerotic lesions [
24]. Induced inflammation in endothelial cells treated with TNF-α or interleukin-1β as well as in mice on LPS administration results in elevation levels of EL mRNA and protein [
25‐
27]. These results suggest that EL expression is regulated by inflammatory stimuli.
So far, evidence for the role of HDL-C on cognitive decline and dementia, and that for the role of EL on determining of HDL-C has been separately accumulated; the link between EL and cognition has not yet been studied. Thus, in the current study, we examined whether the blood EL concentrations were associated with cognitive impairment in a cross-sectional study of elderly people in Korea.
Discussion
In the present study, we demonstrated that plasma EL concentration was associated with cognitive impairment in a sample of elderly Korean people. First, we assessed that there was no mean difference in EL levels between diagnostic groups of dementia, MCI and NC. Secondly, we used CDR, which represent dementia severity, to compare the differences in EL levels between the degree of cognitive impairment. Levels of plasma EL were significantly higher in the CDR1 group compared to both the less severe stages (CDR0 and CDR0.5) and the more severe stage (CDR2). Prior to the CDR2 stage, EL levels had a tendency to increase with increasing severity of dementia. Thirdly, we used the MMSE score to reconfirm the relevance between cognitive impairment and EL. Elevated EL levels were significantly associated with reduction of cognitive function.
This is the first study to determine the association between EL and cognitive function. Elevated EL levels in individuals under CDR1 were significantly correlated with cognitive impairment, as assessed by the MMSE. Moreover, logistic regression analysis of the association between upper EL (> 31.6) and cognitive impairment (MMSE score ≤ 25) showed that participants with an upper EL range had at a higher risk (adjusted Odds Ratio = 5.6;
p-value = 0.016) of cognitive impairment than those with a lower range. Recently, a relevant study investigated the effect of EL common variant on AD [
36]. The EL variant carrier suggested showing at a higher risk of AD.
EL facilitates the hydrolysis of HDL phospholipids and clears HDL-C from the circulation [
16]. EL is known as a major regulator of HDL-C and does not affect other lipid parameters [
20,
21,
23]. High HDL-C has been associated with better memory performance, while low HDL-C has been associated with a decline in memory and cognition [
37‐
39]. Consistent with this work, we observed higher HDL-C levels when there were lower EL levels (Additional file
1: Fig. S2). However, other lipid profiles, such as TC, LDL-C, and triglyceride (TG), were not correlated with EL. Notably, there was a significant difference in EL levels between CDR groups (Fig.
1), but no significant differences in HDL-C levels between CDR groups (
p = 0.85, Additional file
1: Table S2). These results suggest that EL concentration may better reflect the severity of dementia than HDL-C levels.
Inflammation which is a necessary and adaptive defense response to different harmful stimuli has been linked to dementia [
40‐
42]. Systemic and chronic inflammation in which immune system is over-activated, can lead to an attack on healthy brain cells and the subsequent progression to dementia [
43,
44]. Infectious pathogens, such as fungus [
45,
46], bacteria [
47], viruses [
48] can directly and indirectly induce neuro-inflammation, leading to AD pathology [
49]. Consistent with these findings, we observed that EL was correlated with peripheral platelet and white blood cell counts, which are blood inflammatory markers [
50,
51]. These results are consistent with evidence that EL levels are positively correlated with other inflammatory markers, C-reactive protein and interleukin 6 [
52‐
54], and that its mRNA and protein levels are regulated by cytokine and LPS [
25‐
27].
We found that EL levels tended to increase with dementia severity prior to the CDR2 stage, but decreased at CDR2 and CDR3 stages. This pattern, which shows the highest peak in the middle of disease progression, is similar to the previous results of MCP-1 and sTREM2 studies [
55,
56]. Higher levels of inflammation have observed in earlier stages of the dementia, suggesting that inflammation precedes development of dementia. [
55,
57]. Therefore, the likely reason for highest pattern is that EL levels may be relevant in inflammation. On the other hand, EL levels in the late AD stage might be an effect of drug treatment for conditions such as AD and other concomitant disorders such as hypercholesterolemia. Statins cause a decrease in the expression of EL as well as an increase in HDL-C [
58,
59]. Additionally, because of the pro-inflammatory effect resulting in EL expression, anti inflammatory drugs may induce EL inactivation [
60]. Most patients with AD have a comorbidity, which can include hypertension (20–30%), being overweight or obese (20–40%), diabetes (20–25%), hypercholesterolemia (> 40%), anemia (> 20%), or cerebrovascular damage (60%) [
61]; comorbidities require the administration of multiple drugs concurrently. This polypharmacy might lead to lower EL concentrations in patients with severe AD.
This study has some limitations. First, the average participant age was so high (average 75.8 years old) that even the NC group was likely to have slight cognitive loss. In fact, some participants felt subjective memory impairment. Indeed, there were no significant differences in CDR and CDR-SOB scores between the MCI (CDR 0.5 ± 0.1, CDR-SOB 1.5 ± 1.1) and NC (CDR 0.4 ± 0.2, CDR-SOB 0.7 ± 0.4) groups, although the CDR and CDR-SOB scores were greater in patients with AD (CDR 1.5 ± 0.8, CDR-SOB 8.8 ± 4.7). This may have resulted in the absence of any significant differences in the mean EL concentrations between diagnostic groups. Second, this study did not completely exclude the effect of drugs on EL levels. When we adjusted for disease history, significance of the adjusted OR and 95% CI of cognitive impairment in the upper EL range was maintained. Nonetheless, the information of disease history was derived from questionnaires and might lead to inaccuracies due to errors in subjective memory. Third, this was a single center study. Small and single center study may be in implicit bias regarding to ethnicity. The samples might not be representative, because we performed continuously rather than random sampling. Other center or multi-center validation studies are needed to address sampling errors and limitation of single center study. This was also a cross sectional study, and thus, the causal relationship between EL and cognitive impairment could not be determined. Further prospective and retrospective studies are required to assess the risk factors of EL on cognitive decline.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.